DWA
PTGX icon

Dorsey Wright & Associates’s Protagonist Therapeutics PTGX Stock Holding History

Dorsey Wright & Associates’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-748
Closed -$9K – 332
2019
Q3 		$9K Buy
+748
New +$9.43K ﹤0.01% 273

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Dorsey Wright & Associates's PTGX Position: Q4 2019 in Review

Dorsey Wright & Associates sold out of Protagonist Therapeutics (PTGX) in Q4 2019, closing a stake of 748 shares — an estimated $9K sold.

Dorsey Wright & Associates first reported a position in PTGX in Q3 2019 and held it in 1 quarter. The position peaked at $9K in Q3 2019. 81 funds tracked by Wall St. Rank hold PTGX as of Q4 2019.

  • Dorsey Wright & Associates reported no remaining Protagonist Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 748 Protagonist Therapeutics shares in Q4 2019, an estimated $9K.
  • Dorsey Wright & Associates first reported a position in Protagonist Therapeutics in Q3 2019 and held it in 1 quarter.
  • Dorsey Wright & Associates's Protagonist Therapeutics position peaked at $9K in Q3 2019.
  • 81 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2019.

Based on Dorsey Wright & Associates's 13F filing for Q4 2019, filed 31 Jan 2020.